HRP20161398T1 - Anti-idiotip-protutijelo protiv protutijela koje je protiv amiloid-beta-peptida - Google Patents
Anti-idiotip-protutijelo protiv protutijela koje je protiv amiloid-beta-peptida Download PDFInfo
- Publication number
- HRP20161398T1 HRP20161398T1 HRP20161398TT HRP20161398T HRP20161398T1 HR P20161398 T1 HRP20161398 T1 HR P20161398T1 HR P20161398T T HRP20161398T T HR P20161398TT HR P20161398 T HRP20161398 T HR P20161398T HR P20161398 T1 HRP20161398 T1 HR P20161398T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- amyloid
- peptide
- conjugated
- cell line
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims 8
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims 8
- 230000003302 anti-idiotype Effects 0.000 title 1
- 238000003018 immunoassay Methods 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 3
- 230000001900 immune effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000007790 solid phase Substances 0.000 claims 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims 2
- 102000003992 Peroxidases Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 2
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (5)
1. Uporaba protutijela koje se veže na područje određene komplementarnosti od protutijela za amiloid-β-peptid i koje se veže na isti epitop ili na preklapajući epitop kao i protutijelo koje se dobiva iz stanične linije DSM ACC2939, naznačena time, da je za imunološko određivanje protutijela za amiloid-β-peptid, u uzorku uporabom imunološke analize, pri čemu varijabilna domena jakog lanca protutijela za amiloid-β-peptid, sadrži CDR3 s aminokiselinskom sekvencom odabranom od SEQ ID NO:1, 2 ili 3, te varijabilna domena slabog lanca navedenog protutijela za amiloid-β-peptid, sadrži CDR3 s aminokiselinskom sekvencom odabranom od SEQ ID NO:4, 5 ili 6.
2. Protutijelo, naznačeno time, da se dobiva iz stanične linije DSM ACC2939.
3. Postupak za imunološko određivanje protutijela za amiloid-β-peptid, naznačen time, da se provodi u uzorku uporabom imunološke analize koja se primjenjuje na protutijelu koje se dobiva iz stanične linije DSM ACC2939, pri čemu imunološka analiza obuhvaća protutijelo za hvatanje, protutijelo za traganje i protutijelo za otkrivanje, dok spomenuto protutijelo za hvatanje je biotinilirano anti-idiotipično protutijelo koje je protiv protutijela za amiloid-β-peptid, dobiveno iz stanične linije DSM ACC2939, i konjugirano preko streptavidina na krutu fazu, gdje protutijelo za traganje je anti-idiotipično protutijelo koje je protiv protutijela za amiloid-β-peptid, dobiveno iz stanične linije DSM ACC2939, i konjugirano na digoksigenin koji služi kao oznaka koja se može otkrivati, te spomenuto protutijelo za otkrivanje je protutijelo protiv digoksigenina, konjugirano na peroksidazu.
4. Postupak za imunološko određivanje protutijela za amiloid-β-peptid, naznačen time, da se provodi u uzorku uporabom imunološke analize koja se primjenjuje na protutijelu koje se dobiva iz stanične linije DSM ACC2939, pri čemu imunološka analiza obuhvaća amiloid-β-peptid konjugiran na krutu fazu, anti-idiotipično protutijelo koje je protiv protutijela za amiloid-β-peptid, dobiveno iz stanične linije DSM ACC2939, konjugirano na digoksigenin koji služi kao oznaka koja se može otkrivati, te protutijelo za otkrivanje protiv digoksigenina, konjugirano na peroksidazu.
5. Postupak prema bilo kojem od zahtjeva 3 do 4, naznačen time, da imunološka analiza obuhvaća protutijelo za hvatanje i protutijelo za traganje, pri čemu spomenuto protutijelo za hvatanje je mješavina koja sadrži najmanje dva od navedenih protutijela koja se razlikuju na mjestu protutijela, na kojem su ona konjugirana na krutu fazu, dok protutijelo za traganje je mješavina iz navedenog protutijela, koja sadrži najmanje dva od navedenih protutijela koja se razlikuju na mjestu protutijela, na kojem su ona konjugirana na oznaku koja se može otkrivati.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08022235 | 2008-12-22 | ||
| EP09796629.5A EP2379601B1 (en) | 2008-12-22 | 2009-12-18 | Anti-idiotype antibody against an antibody against the amyloid beta peptide |
| PCT/EP2009/009160 WO2010072384A1 (en) | 2008-12-22 | 2009-12-18 | ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID β PEPTIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161398T1 true HRP20161398T1 (hr) | 2016-12-16 |
Family
ID=40581970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161398TT HRP20161398T1 (hr) | 2008-12-22 | 2016-10-25 | Anti-idiotip-protutijelo protiv protutijela koje je protiv amiloid-beta-peptida |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8614297B2 (hr) |
| EP (1) | EP2379601B1 (hr) |
| JP (1) | JP5642702B2 (hr) |
| KR (2) | KR20110086182A (hr) |
| CN (2) | CN102257010A (hr) |
| AR (1) | AR074816A1 (hr) |
| AU (1) | AU2009331900A1 (hr) |
| BR (1) | BRPI0923544B1 (hr) |
| CA (1) | CA2746779C (hr) |
| CY (1) | CY1118420T1 (hr) |
| DK (1) | DK2379601T3 (hr) |
| ES (1) | ES2595981T3 (hr) |
| HR (1) | HRP20161398T1 (hr) |
| HU (1) | HUE030478T2 (hr) |
| IL (1) | IL213343A0 (hr) |
| LT (1) | LT2379601T (hr) |
| MX (2) | MX2011006641A (hr) |
| PL (1) | PL2379601T3 (hr) |
| PT (1) | PT2379601T (hr) |
| SI (1) | SI2379601T1 (hr) |
| TW (1) | TWI424162B (hr) |
| WO (1) | WO2010072384A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| TW201348246A (zh) * | 2012-05-21 | 2013-12-01 | Abbvie Inc | 利用蛋白質ａ親和性層析之人類、人類化或嵌合抗體之新穎純化 |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EP3176580A1 (en) * | 2015-12-01 | 2017-06-07 | Roche Diagnostics GmbH | Method for reduction of interferences in immunoassays |
| JP6918808B2 (ja) * | 2016-08-31 | 2021-08-11 | 栄研化学株式会社 | 異なる方式で抗原を固定化した抗原担持不溶性担体粒子を用いる抗体測定法、抗体測定用試薬 |
| CN113811770B (zh) * | 2019-05-13 | 2024-06-28 | 豪夫迈·罗氏有限公司 | 抑制干扰的药代动力学免疫测定 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219730A (en) * | 1982-09-28 | 1993-06-15 | New York University | Idiotype-anti-idiotype immunoassay |
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| EP0170302A1 (fr) | 1984-06-27 | 1986-02-05 | l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire | Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques |
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| EP0243471A4 (en) | 1985-10-22 | 1989-07-11 | Cooper Lipotech Inc | SOLID PHASE LIPOSOME IMMUNOANALYSIS SYSTEM. |
| ATE180057T1 (de) | 1988-11-03 | 1999-05-15 | Igen Int Inc | Elektrochemilumineszente testverfahren |
| US5068088A (en) | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
| WO1990006515A1 (en) | 1988-12-09 | 1990-06-14 | Centocor, Inc. | Anti-idiotopic immunometric assay |
| IL100866A (en) | 1991-02-06 | 1995-10-31 | Igen Inc | Luminescence test method and device based on magnetic tiny particles, containing many magnets |
| NZ255041A (en) | 1992-07-13 | 1996-11-26 | Bionebraska Inc | Preparation of a recombinant single copy polypeptide or portion thereof modified with a terminal alpha amino carbon reactive group and reactive side chain groups involving biologically added protective groups |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US7790856B2 (en) * | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| CZ2008595A3 (cs) * | 2000-02-24 | 2017-05-03 | Washington University | Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci |
| US7700751B2 (en) * | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| WO2003016466A2 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US7745569B2 (en) * | 2003-04-07 | 2010-06-29 | The Regents Of The University Of California | Amyloid specific binding peptides and detecting abeta peptide |
| PE20050627A1 (es) * | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| EP1660533A4 (en) * | 2003-09-12 | 2009-10-21 | Univ California | SPECIFIC MONOCLONAL ANTIBODIES MADE FROM PROTEINS OF DIFFERENT SEQUENCES FOR HIGHLY MOLECULAR AGGREGATIVE INTERMEDIATE PRODUCTS OF AMYLOIDS |
| US20050130246A1 (en) | 2003-10-27 | 2005-06-16 | Hossein Salimi-Moosavi | Detecting human anti-therapeutic antibodies |
| WO2005105998A1 (ja) * | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント |
| US7807165B2 (en) * | 2004-07-30 | 2010-10-05 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| PE20061152A1 (es) * | 2004-12-15 | 2006-10-13 | Neuralab Ltd | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| UY29504A1 (es) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| JP4902674B2 (ja) | 2006-03-09 | 2012-03-21 | エフ．ホフマン−ラ ロシュ アーゲー | 抗薬物抗体アッセイ法 |
| EP1917854A1 (en) | 2006-11-06 | 2008-05-07 | F. Hoffmann-La Roche Ag | Method for producing anti idiotypic antibodies |
| US20080127359A1 (en) * | 2006-11-06 | 2008-05-29 | Hermann Beck | Method for producing anti-idiotypic antibodies |
| TWI434855B (zh) * | 2006-11-21 | 2014-04-21 | Hoffmann La Roche | 結合物及其在免疫分析中作為參考標準之用途 |
-
2009
- 2009-12-15 US US12/637,833 patent/US8614297B2/en active Active
- 2009-12-18 MX MX2011006641A patent/MX2011006641A/es active IP Right Grant
- 2009-12-18 KR KR1020117014278A patent/KR20110086182A/ko active Application Filing
- 2009-12-18 AU AU2009331900A patent/AU2009331900A1/en not_active Abandoned
- 2009-12-18 SI SI200931544A patent/SI2379601T1/sl unknown
- 2009-12-18 PT PT97966295T patent/PT2379601T/pt unknown
- 2009-12-18 CA CA2746779A patent/CA2746779C/en active Active
- 2009-12-18 HU HUE09796629A patent/HUE030478T2/en unknown
- 2009-12-18 CN CN2009801517154A patent/CN102257010A/zh active Pending
- 2009-12-18 KR KR1020137019063A patent/KR101777899B1/ko active IP Right Grant
- 2009-12-18 DK DK09796629.5T patent/DK2379601T3/en active
- 2009-12-18 EP EP09796629.5A patent/EP2379601B1/en active Active
- 2009-12-18 BR BRPI0923544-2A patent/BRPI0923544B1/pt not_active IP Right Cessation
- 2009-12-18 WO PCT/EP2009/009160 patent/WO2010072384A1/en active Application Filing
- 2009-12-18 CN CN201710026240.2A patent/CN106990251B/zh active Active
- 2009-12-18 JP JP2011542710A patent/JP5642702B2/ja active Active
- 2009-12-18 PL PL09796629T patent/PL2379601T3/pl unknown
- 2009-12-18 LT LTEP09796629.5T patent/LT2379601T/lt unknown
- 2009-12-18 ES ES09796629.5T patent/ES2595981T3/es active Active
- 2009-12-18 MX MX2014009062A patent/MX352117B/es unknown
- 2009-12-21 TW TW098143984A patent/TWI424162B/zh not_active IP Right Cessation
- 2009-12-21 AR ARP090104999A patent/AR074816A1/es unknown
-
2011
- 2011-06-02 IL IL213343A patent/IL213343A0/en unknown
-
2013
- 2013-08-07 US US13/960,893 patent/US9547010B2/en active Active
-
2016
- 2016-10-25 HR HRP20161398TT patent/HRP20161398T1/hr unknown
- 2016-11-04 CY CY20161101134T patent/CY1118420T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161398T1 (hr) | Anti-idiotip-protutijelo protiv protutijela koje je protiv amiloid-beta-peptida | |
| HRP20201634T1 (hr) | Monoklonsko protutijelo protiv interleukina-31 | |
| NZ716369A (en) | Anti-ox40 antibodies and methods of using the same | |
| HRP20191886T1 (hr) | Testovi aktivnosti imunološkog toksina botulinuma serotipa a | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| IL275270A (en) | Recombinant scavenger cell surface proteins | |
| JP2016026303A5 (hr) | ||
| NZ630433A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| NZ587198A (en) | Monoclonal antibodies against the rgm a protein and uses thereof | |
| BRPI0715989A8 (pt) | "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" | |
| RS53042B (en) | ANTIBODIES AGAINST ERBB3 AND THEIR USES | |
| BR112012006492A2 (pt) | proteína de fusão de anticorpo multivalente, e, ligação de albumina | |
| WO2012007903A3 (en) | A method of detecting surrogate markers for active tuberculosis in a serum sample | |
| JP2015531768A5 (hr) | ||
| AR077594A1 (es) | Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t) | |
| JP2016505634A5 (hr) | ||
| NZ588713A (en) | Antibodies to receptor of advanced glycation end products (rage) and uses thereof | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| JP2015529202A5 (hr) | ||
| BRPI0511448A (pt) | anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências | |
| WO2006116442A3 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| JP2015527365A5 (hr) | ||
| FR2935384B1 (fr) | Procede de detection du virus de la rougeole, dispositif et kit utilisant ce procede | |
| JP2018527895A5 (hr) | ||
| NZ597611A (en) | Anti notch-1 antibodies |